SANA (Sana Biotechnology, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by SANA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-27 | DHAVALKUMAR DHIRAJLAL PATEL | EVP, Chief Scientific Officer | MIXED | — | — |
| 2026-07-07 | Hans Edgar Bishop | Director | A | — | — |
| 2026-06-05 | Michelle Seitz | Director | A | — | — |
| 2026-06-05 | ROBERT NELSEN | Director | A | — | — |
| 2026-06-05 | Hans Edgar Bishop | Director | A | — | — |
| 2026-06-05 | Joshua H. Bilenker | Director | A | — | — |
| 2026-06-05 | Robert L. Rosiello | Director | A | — | — |
| 2026-06-05 | Patrick Y Yang | Director | A | — | — |
| 2026-06-05 | Richard Mulligan | Director | A | — | — |
| 2026-06-05 | ALISE REICIN | Director | A | — | — |
| 2026-04-08 | Hans Edgar Bishop | Director | A | — | — |
| 2026-03-10 | Susan D. Wyrick | See Remarks | MIXED | — | — |
| 2026-03-10 | Steve Harr | President & CEO | MIXED | — | — |
| 2026-03-06 | Steve Harr | President & CEO | A | — | — |
| 2026-03-06 | Susan D. Wyrick | See Remarks | A | — | — |
| 2026-03-04 | Susan D. Wyrick | See Remarks | MIXED | — | — |
| 2026-02-18 | Brian Piper | EVP, Chief Financial Officer | A | — | — |
| 2026-01-06 | Hans Edgar Bishop | Director | A | — | — |
| 2026-01-06 | Susan D. Wyrick | See Remarks | MIXED | — | — |
| 2025-12-16 | Susan D. Wyrick | See Remarks | MIXED | — | — |
| 2025-12-05 | Susan D. Wyrick | See Remarks | MIXED | — | — |
| 2025-10-07 | Hans Edgar Bishop | Director | A | — | — |
| 2025-07-08 | Hans Edgar Bishop | Director | A | — | — |
| 2025-06-09 | Joshua H. Bilenker | Director | A | — | — |
| 2025-06-09 | ROBERT NELSEN | Director | A | — | — |
| 2025-06-09 | Mary Agnes Wilderotter | Director | A | — | — |
| 2025-06-09 | Michelle Seitz | Director | A | — | — |
| 2025-06-09 | ALISE REICIN | Director | A | — | — |
| 2025-06-09 | Hans Edgar Bishop | Director | A | — | — |
| 2025-06-09 | Richard Mulligan | Director | A | — | — |
| 2025-06-09 | Robert L. Rosiello | Director | A | — | — |
| 2025-06-09 | Patrick Y Yang | Director | A | — | — |
| 2025-04-08 | Hans Edgar Bishop | Director | A | — | — |
| 2025-03-10 | Bernard J Cassidy | EVP & General Counsel | MIXED | — | — |
| 2025-03-10 | Steve Harr | President & CEO | MIXED | — | — |
| 2025-03-10 | Susan D. Wyrick | See Remarks | MIXED | — | — |
| 2025-03-03 | Susan D. Wyrick | See Remarks | MIXED | — | — |
| 2025-01-10 | FMR LLC | 10%+ Owner | Sell | — | — |
| 2025-01-07 | Hans Edgar Bishop | Director | A | — | — |
| 2025-01-03 | Susan D. Wyrick | See Remarks | MIXED | — | — |
| 2024-10-09 | Hans Edgar Bishop | Director | A | — | — |
| 2024-09-26 | Richard Mulligan | Director | Sell | — | — |
| 2024-07-15 | Mary Agnes Wilderotter | Director | A | — | — |
| 2024-07-15 | Hans Edgar Bishop | Director | A | — | — |
| 2024-07-15 | Douglas G. Cole | Director | A | — | — |
| 2024-07-15 | Joshua H. Bilenker | Director | A | — | — |
| 2024-07-15 | Richard Mulligan | Director | A | — | — |
| 2024-07-15 | ROBERT NELSEN | Director | A | — | — |
| 2024-07-15 | Patrick Y Yang | Director | A | — | — |
| 2024-07-15 | Michelle Seitz | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 12,447,375 | — |
| — | 10%+ Owner | 12,446,022 | — |
| — | 10%+ Owner | 11,718,750 | — |
| — | 10%+ Owner | 11,585,199 | — |
| — | 10%+ Owner | 11,441,326 | — |
| — | 10%+ Owner | 10,743,293 | — |
| — | 10%+ Owner | 10,667,387 | — |
| — | 10%+ Owner | 10,303,750 | — |
| — | President & CEO | 8,124,070 | — |
| — | Director | 5,854,800 | — |
| — | 10%+ Owner | 4,707,423 | — |
| — | Director | 2,848,121 | — |
| — | Director | 1,830,610 | — |
| — | EVP, Head of Development & CMO | 1,551,627 | — |
| — | EVP, Chief Business Officer | 867,455 | — |
| — | EVP & General Counsel | 505,208 | — |
| — | EVP, Chief Scientific Officer | 224,510 | — |
| — | See Remarks | 197,241 | — |
| — | Director | 149,250 | — |
| — | EVP & General Counsel | 112,990 | — |
| — | Director | 20,000 | — |
| — | Director | 7,106 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SANA quote page; the site-wide leaderboard is on the insider transactions hub.